This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ALISO VIEJO, Calif.,
March 16, 2012 /PRNewswire/ --
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of
Rohan Palekar to the position of senior vice president and chief commercial officer. Mr. Palekar will be responsible for leading all of the company's commercial activities.
"Rohan has an outstanding track record of success in biopharmaceutical sales and marketing," said
Keith A. Katkin, president and CEO of Avanir. "I am delighted that we were able to attract someone of Rohan's caliber to spearhead our global commercial activities. His comprehensive background in healthcare sales and marketing, new product planning and strategic analysis, as well as his leadership capabilities, will be pivotal to the continued commercial success of Avanir."
Mr. Palekar has over 20 years of experience in the biopharmaceutical industry and has worked on significant brands including Remicade® and Stelara®, as well as the investigational therapy MDV3100. Mr. Palekar's most recent commercial leadership role was as chief commercial officer for Medivation, where he was responsible for all commercial activities, CMC & manufacturing and public relations functions. Prior to Medivation, Mr. Palekar spent 16+ years at Johnson & Johnson in various senior commercial and strategic management roles, most recently as a vice president of sales & marketing at Centocor, where he successfully launched two new indications for Remicade. Prior to that, Mr. Palekar was the worldwide vice president of immunology and held marketing leadership roles at McNeil Consumer and Specialty Pharmaceuticals. Mr. Palekar earned his MBA from the Amos Tuck School of Business Administration
Dartmouth College and his BA/BS in Law and Accounting from the
University of Bombay.
"I am excited to be joining the Avanir team and working with this talented group to help make NUEDEXTA available to patients and physicians worldwide," said
Rohan Palekar, senior vice president and chief commercial officer of Avanir. "The growth opportunity that lies ahead for Avanir is incredible and I look forward to the chance to positively affect the lives of patients suffering from pseudobulbar affect and other CNS disorders."
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit
Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.